Raheela Ashfaq
YOU?
Author Swipe
View article: Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 37K, Detailed RT-PCR results.
View article: Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 4 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 37K, Detailed RT-PCR results.
View article: Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate…
View article: Supplementary Figure 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Figure 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 3706K, Pathway Analysis.
View article: Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Data from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
Five years of tamoxifen reduces breast cancer risk by nearly 50% but is associated with significant side effects and toxicities. A better understanding of the direct and indirect effects of tamoxifen in benign breast tissue could elucidate…
View article: Supplementary Table 2 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 2 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 19K, Genes modulated by tamoxifen but not placebo in an analysis restricted to premenopausal women.
View article: Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 42K, RT-PCR primer sequences.
Data from HMGA2 Participates in Transformation in Human Lung Cancer Open
Although previous studies have established a prominent role for HMGA1 (formerly HMG-I/Y) in aggressive human cancers, the role of HMGA2 (formerly HMGI-C) in malignant transformation has not been clearly defined. The HMGA gene family includ…
Data from HMGA2 Participates in Transformation in Human Lung Cancer Open
Although previous studies have established a prominent role for HMGA1 (formerly HMG-I/Y) in aggressive human cancers, the role of HMGA2 (formerly HMGI-C) in malignant transformation has not been clearly defined. The HMGA gene family includ…
View article: Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 3 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 42K, RT-PCR primer sequences.
View article: Supplementary Figure 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Figure 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 3706K, Pathway Analysis.
Supplementary Data from HMGA2 Participates in Transformation in Human Lung Cancer Open
Supplementary Data from HMGA2 Participates in Transformation in Human Lung Cancer
View article: Supplementary Table 2 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 2 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 19K, Genes modulated by tamoxifen but not placebo in an analysis restricted to premenopausal women.
View article: Supplementary Table 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 67K, Genes modulated by tamoxifen but not placebo in an analysis that combined pre- and post-menopausal women.
View article: Supplementary Table 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction
Supplementary Table 1 from Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction Open
PDF file - 67K, Genes modulated by tamoxifen but not placebo in an analysis that combined pre- and post-menopausal women.
Supplementary Data from HMGA2 Participates in Transformation in Human Lung Cancer Open
Supplementary Data from HMGA2 Participates in Transformation in Human Lung Cancer
View article: Data from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Data from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells Open
The epidermal growth factor receptor (EGFR) gene is commonly amplified and rearranged in glioblastoma multiforme leading to overexpression of wild-type and mutant EGFRs. Expression of wild-type EGFR ligands, such as transforming growth fac…
View article: Supplementary Table 1 from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Supplementary Table 1 from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells Open
Supplementary Table 1 from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
View article: Data from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Data from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells Open
The epidermal growth factor receptor (EGFR) gene is commonly amplified and rearranged in glioblastoma multiforme leading to overexpression of wild-type and mutant EGFRs. Expression of wild-type EGFR ligands, such as transforming growth fac…
View article: Supplementary Table 1 from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Supplementary Table 1 from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells Open
Supplementary Table 1 from Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Data from The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis Open
Uterine cancer is the most common cancer of the female genital tract and is the fourth most frequent cause of cancer death in women in the U.S. Despite the high prevalence of uterine cancers, the molecular events that lead to neoplastic tr…
Supplementary Figures 1-3 from The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis Open
Supplementary Figures 1-3 from The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis
Data from The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis Open
Uterine cancer is the most common cancer of the female genital tract and is the fourth most frequent cause of cancer death in women in the U.S. Despite the high prevalence of uterine cancers, the molecular events that lead to neoplastic tr…
Supplementary Figures 1-3 from The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis Open
Supplementary Figures 1-3 from The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis
View article: Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology
Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology Open
Most prior studies of primary diagnosis in surgical pathology using whole slide imaging (WSI) versus microscopy have focused on specific organ systems or included relatively few cases. The objective of this study was to demonstrate that WS…
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial Open
National Cancer Institute and Genentech.